Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

753
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
753
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

187
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
187
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

674
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
674
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

188
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
188

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026
Same author

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Blood·2026
Same author

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

American journal of hematology·2026
Same author

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Blood cancer journal·2026
Same author

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Blood advances·2026
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Dec 4, 2025

A Novel Microsurgical Model for Heterotopic, En Bloc Chest Wall, Thymus, and Heart Transplantation in Mice
12:24

A Novel Microsurgical Model for Heterotopic, En Bloc Chest Wall, Thymus, and Heart Transplantation in Mice

Published on: January 23, 2016

9.6K

Solid Organ Transplantation.

Susan Bal1, Heather J Landau2

  • 1Division of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, 1802 6th Avenue South, Birmingham, AL 35294, USA. Electronic address: https://twitter.com/SusanBal9.

Hematology/Oncology Clinics of North America
|October 25, 2020
PubMed
Summary
This summary is machine-generated.

Patients with light chain (AL) amyloidosis may achieve long-term survival through combined organ transplantation and hematologic disease control. This approach enables eligibility for effective therapies like high-dose therapy and stem cell transplantation.

Keywords:
AmyloidosisCardiomyopathyDirected-donorESRDExtended-donorOrgan transplantation

More Related Videos

Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
09:03

Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation

Published on: November 17, 2014

10.0K
Vascularized Composite Upper Limb Allograft Harvesting for Proximal Arm Allotransplantation
08:11

Vascularized Composite Upper Limb Allograft Harvesting for Proximal Arm Allotransplantation

Published on: June 13, 2025

377

Related Experiment Videos

Last Updated: Dec 4, 2025

A Novel Microsurgical Model for Heterotopic, En Bloc Chest Wall, Thymus, and Heart Transplantation in Mice
12:24

A Novel Microsurgical Model for Heterotopic, En Bloc Chest Wall, Thymus, and Heart Transplantation in Mice

Published on: January 23, 2016

9.6K
Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
09:03

Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation

Published on: November 17, 2014

10.0K
Vascularized Composite Upper Limb Allograft Harvesting for Proximal Arm Allotransplantation
08:11

Vascularized Composite Upper Limb Allograft Harvesting for Proximal Arm Allotransplantation

Published on: June 13, 2025

377

Area of Science:

  • Hematology
  • Transplant Surgery
  • Oncology

Background:

  • Light chain (AL) amyloidosis poses significant challenges to patient survival.
  • Limited organ involvement is crucial for successful treatment strategies.
  • Restoration of cardiac function via transplantation is key for further therapeutic options.

Purpose of the Study:

  • To evaluate the efficacy of combined organ transplantation and disease-directed therapies in AL amyloidosis.
  • To explore strategies for improving organ availability for AL amyloidosis patients.
  • To address concerns regarding graft recurrence and disease progression.

Main Methods:

  • Selection of patients with AL amyloidosis and limited organ involvement.
  • Utilizing directed-donor, exchange, and extended-donor organ programs for transplantation.
  • Administering high-dose therapy and autologous stem cell transplantation post-transplant.
  • Employing plasma cell-directed therapies to manage disease recurrence and progression.

Main Results:

  • Combined approach can lead to long-term survival in select AL amyloidosis patients.
  • Organ transplantation facilitates access to critical disease-modifying treatments.
  • Improved organ availability through various transplantation programs enhances treatment options.

Conclusions:

  • Organ transplantation combined with hematologic disease control offers a viable path to long-term survival for select AL amyloidosis patients.
  • Effective management of plasma cell disorders is essential for mitigating risks of graft recurrence and disease progression.